Last updated October 21, 2026. Approval line checked October 21, 2026. Compounding sources checked October 10, 2026.
FDA status
Not approved
Not approved. This record is not an FDA-approved drug product. Approval, where it exists, is specific to a drug product, indication, and route.
FDA primary source on fileBy signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Evidence tier
Animal Only. The tier is the highest indexed study type. It is not a safety rating and it is not an FDA approval. Confidence score 3/5. 0 PubMed citations indexed.
PDA is the arginate salt form of the 15-amino-acid BPC-157 sequence (bepecin di-L-arginine salt); it activates the VEGFR2–Akt–eNOS signaling cascade to promote angiogenesis and restore blood flow to i
What the literature studies
Recovery Research
Evidence tier
Animal Only
Compounding record
Status not verified
Status not verified. Status not verified. Exact FDA substance context: FDA names BPC-157: Nomination withdrawn. The arginate salt is not independently verified; no inference of eligibility from salt substitution. Previously in Category 2; FDA still identifies potential significant safety risks for the named withdrawn substance. Withdrawal is not FDA approval or a determination of safety or compounding eligibility. Research information is not evidence of FDA approval. Approval, where applicable, is specific to a drug product, indication and route.
Regulatory source checked October 10, 2026. This compounding label is separate from the approval line above.
all efficacy data is extrapolated from BPC-157 research conducted with a different salt form, making evidence claims [U
By signing up you agree to get PeptideX update emails. Unsubscribe anytime. Educational only, not medical advice.
Educational only. Not medical advice. This page does not give doses or sourcing. See the medical and editorial disclaimer.